Table 1.
Patient characteristics
| HCs | HOVON139 baseline PB | HOVON139 baseline LN | HOVON139 1-y PB | HOVON141 baseline PB | HOVON141 1-y PB | |
|---|---|---|---|---|---|---|
| N | 10 | 41 | 28 | 11 | 10 | 10 |
| Males, % | 50 | 75.7 | 80.8 | 81.8 | 30.0 | 30.0 |
| Age, y | 63 (45-78) | 71 (57-80) | 71 (57-79) | 71.5 (60-78) | 68 (52-76) | 68 (52-76) |
| CMV positive, % | 83 | 41 | 48 | 64 | Not known | Not known |
| ALC, ×109/L | Not known | 98.6 (3.5-420.7) | 97.3 (18.0-399.0) | 4.8 (2.8-9.9) | 129.8 (20.0-248.9) | 4.8 (3.9-7.6) |
| TTFT, mo | N/A | 28.2 (0.7-244.6) | 28.1 (0.7-244.6) | 18.9 (1.7-244.6) | Not known | Not known |
| Prior treatment, n | N/A | N/A | N/A | N/A | 1 (1-3) | 1 (1-3) |
| Prior chemotherapy, % | N/A | N/A | N/A | N/A | 100 | 100 |
| TTT, mo | N/A | N/A | N/A | N/A | 42.8 (13.8-141.8) | 42.8 (13.8-141.8) |
| Rai stage III-IV, % | N/A | 57.1 | 44.0 | 36.4 | 80 | 80 |
| IgVH status U-CLL, % | N/A | 55.9 | 55.6 | 27.3 | 40 | 40 |
Unless otherwise noted, data are median (range).
ALC, absolute leukocyte count; CMV, cytomegalovirus; N/A, not applicable; TTFT, time to first treatment; TTT, time from last treatment to current treatment; U-CLL, CLL with unmutated immunoglobulin heavy chains.